Phenotype and differentiation patterns of the oval cell lines OC/CDE 6 and OC/CDE 22 derived from the livers of carcinogen-treated rats.
An electron microscopic, immunocytochemical, and enzyme cytochemical analysis of the previously established oval cell lines OC/CDE 6 and OC/CDE 22 was performed to characterize the phenotype and differentiation patterns of long-term cultures of oval cells. It was found that alpha-fetoprotein, albumin, and cytokeratin 19 are present in all cultured cells. This indicates that oval cells constitute a population of immature cells expressing features of the antigenic phenotype of both the hepatocyte and bile ductular cell lineages. An electron microscopic examination revealed a gradual alteration in the ultrastructure of oval cells toward hepatocyte-like cells. The majority of the oval cells were positive for glucose-6-phosphatase activity. A particularly striking observation was that oval cells were heterogeneous in terms of peroxisome content. Only about 50% of the oval cells had peroxisomes in the cytoplasm, these cells probably being part of the hepatocyte lineage. The other cultured cells did not reveal catalase activity and probably represented cells committed to the bile ductular cell lineage. An addition of clofibrate to the culture medium resulted in a marked peroxisome proliferation in all oval cells, indicating that oval cells might be able to change their differentiation pathway depending on environmental influence toward the hepatocyte lineage. It is most intriguing that in oval cells with abundant cytoplasm peroxisome proliferation was accompanied by proliferation of the smooth endoplasmic reticulum (this is a morphological marker of mature hepatocytes). Taken together, our findings suggest that within the oval cell lines OC/CDE 6 and OC/CDE 22 cells undergoing a morphological and functional differentiation along the hepatocyte and bile ductular cell lineages are present.
Radaeva
S
S
Abteilung für Cytopathologie, Deutsches Krebsforschungszentrum, Heidelberg, Germany.
Steinberg
P
P
D015100:3,3'-Diaminobenzidine; D000418:Albumins / Q000032:analysis; D000818:Animals; D000951:Antigens, Neoplasm / Q000032:analysis; D002454:Cell Differentiation / Q000502:physiology; D002471:Cell Transformation, Neoplastic / Q000235:genetics* / Q000473:pathology*; D002796:Choline Deficiency / Q000150:complications; D002994:Clofibrate / Q000494:pharmacology; D005001:Ethionine / Q000494:pharmacology; D005952:Glucose-6-Phosphatase / Q000378:metabolism; D007150:Immunohistochemistry; D007633:Keratins / Q000032:analysis; D008099:Liver / Q000166:cytology* / Q000187:drug effects / Q000502:physiology*; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced* / Q000473:pathology*; D008769:Methylnitronitrosoguanidine; D008854:Microscopy, Electron; D010641:Phenotype; D051381:Rats; D017207:Rats, Sprague-Dawley; D013194:Staining and Labeling / Q000379:methods; D014746:Vimentin / Q000032:analysis; D000509:alpha-Fetoproteins / Q000032:analysis
D000418:Albumins; D000951:Antigens, Neoplasm; D014746:Vimentin; D000509:alpha-Fetoproteins; D008769:Methylnitronitrosoguanidine; D015100:3,3'-Diaminobenzidine; D007633:Keratins; D005952:Glucose-6-Phosphatase; D002994:Clofibrate; D005001:Ethionine